Immunogenicity and efficacy of VLA2001 vaccine against SARS-CoV-2 infection in male cynomolgus macaques.
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
03 Apr 2024
03 Apr 2024
Historique:
received:
22
05
2023
accepted:
21
03
2024
medline:
4
4
2024
pubmed:
4
4
2024
entrez:
3
4
2024
Statut:
epublish
Résumé
The fight against COVID-19 requires mass vaccination strategies, and vaccines inducing durable cross-protective responses are still needed. Inactivated vaccines have proven lasting efficacy against many pathogens and good safety records. They contain multiple protein antigens that may improve response breadth and can be easily adapted every year to maintain preparedness for future seasonally emerging variants. The vaccine dose was determined using ELISA and pseudoviral particle-based neutralization assay in the mice. The immunogenicity was assessed in the non-human primates with multiplex ELISA, neutralization assays, ELISpot and intracellular staining. The efficacy was demonstrated by viral quantification in fluids using RT-qPCR and respiratory tissue lesions evaluation. Here we report the immunogenicity and efficacy of VLA2001 in animal models. VLA2001 formulated with alum and the TLR9 agonist CpG 1018™ adjuvant generate a Th1-biased immune response and serum neutralizing antibodies in female BALB/c mice. In male cynomolgus macaques, two injections of VLA2001 are sufficient to induce specific and polyfunctional CD4 We demonstrate that the VLA2001 adjuvanted vaccine is immunogenic both in mouse and NHP models and prevent cynomolgus macaques from the viruses responsible of COVID-19. Mass vaccination in response to the COVID-19 pandemic has substantially reduced the number of severe cases and hospitalizations. As the virus continues to evolve and give rise to new variants that cause local outbreaks, there is a need to develop new vaccine candidates capable of stopping the viral transmission. In this study, we explore the immune responses induced by the vaccine candidate VLA2001 in animal models. We highlight the vaccine’s ability to induce an immune response capable of blocking the virus and eliminating infected cells. We show that it can protect the host from developing severe disease.
Sections du résumé
BACKGROUND
BACKGROUND
The fight against COVID-19 requires mass vaccination strategies, and vaccines inducing durable cross-protective responses are still needed. Inactivated vaccines have proven lasting efficacy against many pathogens and good safety records. They contain multiple protein antigens that may improve response breadth and can be easily adapted every year to maintain preparedness for future seasonally emerging variants.
METHODS
METHODS
The vaccine dose was determined using ELISA and pseudoviral particle-based neutralization assay in the mice. The immunogenicity was assessed in the non-human primates with multiplex ELISA, neutralization assays, ELISpot and intracellular staining. The efficacy was demonstrated by viral quantification in fluids using RT-qPCR and respiratory tissue lesions evaluation.
RESULTS
RESULTS
Here we report the immunogenicity and efficacy of VLA2001 in animal models. VLA2001 formulated with alum and the TLR9 agonist CpG 1018™ adjuvant generate a Th1-biased immune response and serum neutralizing antibodies in female BALB/c mice. In male cynomolgus macaques, two injections of VLA2001 are sufficient to induce specific and polyfunctional CD4
CONCLUSIONS
CONCLUSIONS
We demonstrate that the VLA2001 adjuvanted vaccine is immunogenic both in mouse and NHP models and prevent cynomolgus macaques from the viruses responsible of COVID-19.
Mass vaccination in response to the COVID-19 pandemic has substantially reduced the number of severe cases and hospitalizations. As the virus continues to evolve and give rise to new variants that cause local outbreaks, there is a need to develop new vaccine candidates capable of stopping the viral transmission. In this study, we explore the immune responses induced by the vaccine candidate VLA2001 in animal models. We highlight the vaccine’s ability to induce an immune response capable of blocking the virus and eliminating infected cells. We show that it can protect the host from developing severe disease.
Autres résumés
Type: plain-language-summary
(eng)
Mass vaccination in response to the COVID-19 pandemic has substantially reduced the number of severe cases and hospitalizations. As the virus continues to evolve and give rise to new variants that cause local outbreaks, there is a need to develop new vaccine candidates capable of stopping the viral transmission. In this study, we explore the immune responses induced by the vaccine candidate VLA2001 in animal models. We highlight the vaccine’s ability to induce an immune response capable of blocking the virus and eliminating infected cells. We show that it can protect the host from developing severe disease.
Identifiants
pubmed: 38570605
doi: 10.1038/s43856-024-00488-w
pii: 10.1038/s43856-024-00488-w
doi:
Types de publication
Journal Article
Langues
eng
Pagination
62Informations de copyright
© 2024. The Author(s).
Références
Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 385, 1172–1183 (2021).
doi: 10.1056/NEJMoa2107659
pubmed: 34192426
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
doi: 10.1056/NEJMoa2035389
pubmed: 33378609
Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577
pubmed: 33301246
Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med. 384, 2187–2201 (2021).
doi: 10.1056/NEJMoa2101544
pubmed: 33882225
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
doi: 10.1016/S0140-6736(20)32661-1
pubmed: 33306989
pmcid: 7723445
Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 21, 950–961 (2021).
doi: 10.1016/S1473-3099(21)00070-0
pubmed: 33705727
pmcid: 8221739
Ismail AlHosani, F. et al. Impact of the Sinopharm’s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). Vaccine 40, 2003–2010 (2022).
doi: 10.1016/j.vaccine.2022.02.039
pubmed: 35193793
pmcid: 8857641
Tanriover, M. D. et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet 398, 213–222 (2021).
doi: 10.1016/S0140-6736(21)01429-X
pubmed: 34246358
pmcid: 8266301
Oster, M. E. et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA 327, 331–340 (2022).
doi: 10.1001/jama.2021.24110
pubmed: 35076665
pmcid: 8790664
Elberry, M. H. et al. A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines. J. Thromb Thrombolysis 53, 798–823 (2022).
doi: 10.1007/s11239-021-02626-w
pubmed: 35157188
pmcid: 8853120
Zeng, B., Gao, L., Zhou, Q., Yu, K. & Sun, F. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. medRxiv, 2021.2009.2023.21264048 (2021). https://doi.org/10.1101/2021.09.23.21264048
Pajon, R. et al. SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088–1091 (2022).
doi: 10.1056/NEJMc2119912
pubmed: 35081298
Altmann, D. M. & Boyton, R. J. COVID-19 vaccination: The road ahead. Science 375, 1127–1132 (2022).
doi: 10.1126/science.abn1755
pubmed: 35271316
Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science 375, 678–680 (2022).
doi: 10.1126/science.abn7591
pubmed: 35040667
pmcid: 9836206
Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. 386, 1532–1546 (2022).
doi: 10.1056/NEJMoa2119451
pubmed: 35249272
Ai, J. et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg Microbes Infect 11, 337–343 (2022).
doi: 10.1080/22221751.2021.2022440
pubmed: 34935594
pmcid: 8788341
Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399, 521–529 (2022).
doi: 10.1016/S0140-6736(22)00094-0
pubmed: 35074136
pmcid: 8782575
Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847–859.e811 (2022).
doi: 10.1016/j.cell.2022.01.015
pubmed: 35139340
pmcid: 8784649
Sallam, M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines (Basel) 9 (2021). https://doi.org/10.3390/vaccines9020160
Ella, R. et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet 398, 2173–2184 (2021).
doi: 10.1016/S0140-6736(21)02000-6
pubmed: 34774196
pmcid: 8584828
de Faria, E. et al. Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report. medRxiv, 2021.2004.2012.21255308 (2021). https://doi.org/10.1101/2021.04.12.21255308
Hitchings, M. D. T. et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. Lancet Reg. Health Am. 1, 100025 (2021).
pubmed: 34386791
pmcid: 8310555
Ranzani, O. T. et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ 374, n2015 (2021).
doi: 10.1136/bmj.n2015
pubmed: 34417194
Medeiros-Ribeiro, A. C. et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat. Med. 27, 1744–1751 (2021).
doi: 10.1038/s41591-021-01469-5
pubmed: 34331051
Lim, W. W., Mak, L., Leung, G. M., Cowling, B. J. & Peiris, M. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2, e423 (2021).
doi: 10.1016/S2666-5247(21)00177-4
pubmed: 34308395
pmcid: 8282488
Cerqueira-Silva, T. et al. The effectiveness of Vaxzevria and CoronaVac vaccines: A nationwide longitudinal retrospective study of 61 million Brazilians (VigiVac-COVID19). medRxiv, 2021.2008.2021.21261501 (2021). https://doi.org/10.1101/2021.08.21.21261501
Sulbaran, G. et al. Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. Cell Rep. Med. 3, 100528 (2022).
doi: 10.1016/j.xcrm.2022.100528
pubmed: 35233549
pmcid: 8784613
Zabaleta, N. et al. An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. Cell Host Microbe 29, 1437–1453.e1438 (2021).
doi: 10.1016/j.chom.2021.08.002
pubmed: 34428428
pmcid: 8346325
Marlin, R. et al. Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques. Nat Commun 12, 5215 (2021).
doi: 10.1038/s41467-021-25382-0
pubmed: 34471122
pmcid: 8410935
Maisonnasse, P. et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature 585, 584–587 (2020).
doi: 10.1038/s41586-020-2558-4
pubmed: 32698191
Maisonnasse, P. et al. COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models. Nat Commun 12, 6097 (2021).
doi: 10.1038/s41467-021-26354-0
pubmed: 34671037
pmcid: 8528857
Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. USA 117, 7001–7003 (2020).
doi: 10.1073/pnas.2002589117
pubmed: 32165541
pmcid: 7132130
Institut Pasteur, Paris. Protocol: Real-time RT-PCR assays for the detection of SARS-CoV-2 (2020).
Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25 (2020). https://doi.org/10.2807/1560-7917.Es.2020.25.3.2000045
Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 465–469 (2020).
doi: 10.1038/s41586-020-2196-x
pubmed: 32235945
Naninck, T. et al. Computed tomography and [(18)F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates. iScience 25, 104101 (2022).
doi: 10.1016/j.isci.2022.104101
pubmed: 35313622
pmcid: 8926429
Lee, G. H. & Lim, S. G. CpG-Adjuvanted Hepatitis B Vaccine (HEPLISAV-B®) Update. Expert Rev. Vaccines 20, 487–495 (2021).
doi: 10.1080/14760584.2021.1908133
pubmed: 33783302
Yadav, P. D. et al. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques. Nat Commun 12, 1386 (2021).
doi: 10.1038/s41467-021-21639-w
pubmed: 33654090
pmcid: 7925524
Solforosi, L. et al. Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP. J. Exp. Med. 218 (2021). https://doi.org/10.1084/jem.20202756
Francica, J. R. et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci. Transl. Med. 13 (2021). https://doi.org/10.1126/scitranslmed.abi4547
Amjadi, M. F. et al. Anti-membrane antibodies persist at least one year and discriminate between past Coronavirus Disease 2019 infection and vaccination. J. Infect Dis. 226, 1897–1902 (2022).
doi: 10.1093/infdis/jiac263
pubmed: 35758987
Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol 5, 1598–1607 (2020).
doi: 10.1038/s41564-020-00813-8
pubmed: 33106674
pmcid: 7610833
Brouwer, P. J. M. et al. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection. Cell 184, 1188–1200.e1119 (2021).
doi: 10.1016/j.cell.2021.01.035
pubmed: 33577765
pmcid: 7834972
Lazarus, R. et al. Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect Dis. 22, 1716–1727 (2022).
doi: 10.1016/S1473-3099(22)00502-3
pubmed: 36075233
pmcid: 9444237